A Phase 3b Study for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) in New and Previously EB-101 Treated Patients
Latest Information Update: 11 Jul 2024
At a glance
- Drugs Prademagene zamikeracel (Primary)
- Indications Epidermolysis bullosa dystrophica
- Focus Adverse reactions; Registrational
- Sponsors Abeona therapeutics
Most Recent Events
- 27 Jun 2024 Planned End Date changed from 1 Dec 2024 to 30 Jun 2025.
- 27 Jun 2024 Planned primary completion date changed from 1 Aug 2024 to 31 Mar 2025.
- 20 Sep 2023 Status has been changed to recruiting.